Goldman Sachs Upgrades Myriad Genetics (MYGN) to Buy

July 2, 2012 7:30 AM EDT Send to a Friend
Get Alerts MYGN Hot Sheet
Price: $32.38 +1.16%

Rating Summary:
    6 Buy, 15 Hold, 2 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 13 | Down: 18 | New: 41
Trade MYGN Now!
Join SI Premium – FREE
Goldman Sachs upgraded Myriad Genetics (NASDAQ: MYGN) from Neutral to Buy with a price target of $29.00 (from $27.00).

The firm cited: (1) we believe the recent reimbursement concerns are overdone and believe that the patent debate does not pose near/medium term risk; (2) MYGN's highly US-focused business offers several new product catalysts; (3) we see potential for improved capital allocation to drive share outperformance in 2H; and (4) we believe the scarcity value of established Diagnostics assets warrants an M&A premium in our price target methodology.

For an analyst ratings summary and ratings history on Myriad Genetics click here. For more ratings news on Myriad Genetics click here.

Shares of Myriad Genetics closed at $23.77 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Hot Upgrades, Upgrades

Related Entities

Goldman Sachs

Add Your Comment